What is B. Riley's Estimate for ARWR FY2025 Earnings?

Key Points

• B. Riley's analyst M. El-Saadi estimates that Arrowhead Pharmaceuticals will achieve earnings per share of $0.82 for FY2025, contrary to the current consensus estimate of ($2.42) per share.
• The stock has recently seen mixed ratings from analysts, with a consensus rating of "Moderate Buy" and an average price target of $43.14.
• Arrowhead Pharmaceuticals reported a Q2 EPS of ($1.26), missing estimates, with revenue at $27.77 million against a consensus of $29.01 million.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at B. Riley issued their FY2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Monday, August 11th. B. Riley analyst M. El-Saadi expects that the biotechnology company will earn $0.82 per share for the year. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. B. Riley also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at $0.69 EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($0.75) EPS, FY2028 earnings at ($2.09) EPS and FY2029 earnings at $0.46 EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the company posted ($1.38) EPS.

A number of other research analysts have also commented on ARWR. Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Royal Bank Of Canada decreased their price objective on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Citigroup reduced their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Finally, TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.14.

Arrowhead Pharmaceuticals Stock Up 3.4%

NASDAQ ARWR opened at $17.80 on Wednesday. The firm has a market cap of $2.46 billion, a PE ratio of -13.91, a price-to-earnings-growth ratio of 25.55 and a beta of 0.94. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $27.34. The stock's 50 day simple moving average is $16.52 and its 200 day simple moving average is $15.92. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,628 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth $49,000. Nisa Investment Advisors LLC grew its stake in Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 1,308 shares during the period. CWM LLC grew its stake in Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Arrowhead Pharmaceuticals by 29.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 1,214 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.